FDA approves Ascendis' weekly growth hormone
A growth hormone for weekly use made by Denmark's Ascendis Pharma may now be commercialized in the US after the public authority approved the company's treatment, Skytrofa.
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY DANIEL FRANK CHRISTENSEN
Danish biotechnology company Ascendis Pharma is now permitted to send its first medication to market in the US.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk tests grand acquisition in phase III trial
For subscribers
Ascendis moves forward with phase III drug
For subscribers
